Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
522.38
+6.04 (+1.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
941,057
Open
515.56
Bid (Size)
520.16 (40)
Ask (Size)
523.80 (40)
Prev. Close
516.34
Today's Range
515.30 - 528.99
52wk Range
374.17 - 560.25
Shares Outstanding
259,428,394
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
Today 9:02 EDT
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Via
The Motley Fool
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
September 22, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Performance
YTD
+15.5%
+15.5%
1 Month
-5.5%
-5.5%
3 Month
+8.8%
+8.8%
6 Month
+15.1%
+15.1%
1 Year
+38.7%
+38.7%
More News
Read More
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
↗
September 20, 2026
Via
The Motley Fool
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?
↗
September 18, 2026
Via
The Motley Fool
2 Reasons to Like VRTX (and 1 Not So Much)
September 18, 2026
Via
StockStory
Topics
Stocks
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
↗
September 17, 2026
Via
The Motley Fool
My Top 5 Favorite Stocks for an Uncertain Market
↗
September 16, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Intellectual Property
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
September 15, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead
↗
September 14, 2026
Via
MarketBeat
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 14, 2026
Via
The Motley Fool
1 Unpopular Stock That Should Get More Attention and 2 We Brush Off
September 14, 2026
Via
StockStory
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis
↗
September 12, 2026
Via
MarketBeat
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
↗
September 12, 2026
Via
MarketBeat
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
September 09, 2026
Via
StockStory
Topics
Artificial Intelligence
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
↗
September 08, 2026
Via
The Motley Fool
Topics
Intellectual Property
Why CRISPR Therapeutics Stock Rocked the Market Last Month
↗
September 08, 2026
Via
The Motley Fool
Where Will CRISPR Therapeutics Stock Be in 5 Years?
↗
September 08, 2026
Via
The Motley Fool
Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick
September 08, 2026
From
Biotech Insider
Via
GlobeNewswire
3 Market-Beating Stocks for Long-Term Investors
September 08, 2026
Via
StockStory
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
↗
September 04, 2026
Via
The Motley Fool
Topics
Intellectual Property
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today
↗
September 04, 2026
Via
Benzinga
3 Stocks Whose Competitive Walls Tower Over Nvidia's
↗
September 03, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
↗
September 02, 2026
Via
The Motley Fool
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
September 01, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
August 31, 2026
Via
StockStory
Topics
Stocks
Frequently Asked Questions
Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 522.38
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 09/24/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 135.52B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 136B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.